HealthDay News — Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study published online July 15 in ...

The final, formatted version of the article will be published soon. To develop and validate a novel digital biomarker, the energy curve of the meibomian gland (MG) edge, to assess MG uneven atrophy ...

Eyelash mites, microscopic arachnids, commonly reside on our faces, particularly around the eyes. While often harmless, an overgrowth can lead to Demodex blepharitis, causing itchy, red, and ...

Viatris Inc., a global healthcare company, announced that a randomized, double-masked, vehicle-controlled, phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ...

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future.

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after six weeks. The trial was a randomized, placebo-controlled, double-masked ...

The company announced that a randomized, double-masked, vehicle-controlled, Phase III study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with ...

Patients in the blepharitis study were randomized to receive either MR-139 or placebo, self-administered to the eyelids twice daily over the 12-week trial period. Looking ahead, analysts tracked by ...

Viatris Chief R&D Officer Philippe Martin said, "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase ...

Investing.com -- Viatris Inc. (NASDAQ: VTRS) stock fell 3.6% after the company announced that its Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint. The randomized, ...